salmeterol xinafoate

Salmeterol xinafoate is a long-acting beta2-adrenergic agonist (LABA) primarily used for the long-term maintenance treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It works by stimulating beta2-adrenergic receptors in the bronchial smooth muscle, leading to bronchodilation and improved airflow. It also exhibits some anti-inflammatory properties by inhibiting the release of inflammatory mediators. Developed by GlaxoSmithKline, it was approved in the US in 1994 and is typically administered via inhalation.

Brand names

SereventSerevent DiskusAeromaxArialAstmeroleFujimycinSalmetedurQitaiSerobidServentZamitrel

Other names

SLMSX